DJIM Trader Alerts to 2011
Up to the minute alerts of the stocks DJIM traders are closely watching for a trade, a heads up of sorts. This section is mostly for the trader during market hours and those who are familiar with the DJIM trading methodology. In an effort to get information to you quickly, these alerts may only contain a few words, maybe only a symbol of the stock. It is best you keep up to date on the activities in Trader Journal as most plays originate from that page. Please remember Alerts are not a license to buy, watch for volume, market conditions and other indicators
_____________________________________________________________________________________________
Vyyo secures additional funding from Goldman, Sachs & Co (VYYO)
Co announces an investment from Goldman, Sachs & Co, an existing investor in Vyyo. The transaction, to be closed within the week, will result in $17.5 mln in new funding and an additional $17.5 mln to pay off the aggregate of notes issued to Goldman Sachs in 2006. The total financing of $35 mln consists of a 5-yr unsecured note convertible into Vyyo common stock at $10 per share. The convertible note will bear a 5% annual interest rate
Alexza Pharma target raised to $19 at JMP (ALXA) 15.21 :JMP raises their tgt on ALXA to $19 from $15, and raises their 2010-11 rev ests for AZ-001 after the co announced yesterday successful Phase II trials for AZ-001 and AZ-004 validate platform and bode well for future clinical data. Based on the data, firm believes that AZ-001 may be more than an acceptable treatment for acute migraine, penetrating the mkt more rapidly than their previous expectations.
OEH got D-graded by BS to peer perform, this stock is huge in institutional support so realistically no one should give a damn as they have their own agenda which is getting a nice price in a takeover. Still, if any sell off happens it would be a buying opp to add in our view. To be safe in any D- grade of a stock, we usually sell early and avoid getting SNCR'd like yesterday or HURC'd(usually a down day proceeds the D-grade, if your stock does not act with rest of mkt, you'll find out soon enough why). If you don't know why your stock gaps lower on volume.,...sell first and ask questions later...It will save you $$
FSLR, pretty well turned yesterday with a little BA help it seems..might it see highs soon?
Those TAILS on the major indices yesterday should get attention of many in days to come.
FSLR. 56.70 now, maybe a turn
HDNG new high,
AMAG building a nice daily chart
Some stocks you may want to look at close to add if not sooner on any pick up
2-4 analysts still to give a few words, hopefully glowing.
Talk of big pharma collaboration for these 2 trials going forward.
These are a few possible catalysts in the near future.
We had VNDA up on DJIM from scratch, ACAD was the most recent flyer and today ALXA(a previous DJIM mention) came out with phase 2 trials that met endpoints. We're not about to attempt to analyze the data, all we care about is market reaction.
Let's see if traders dip into the medicine cabinet for a few ALXA shares. If it gets love, we'll most likely give it some too.